

Patient radiation dose and fluoroscopy time during ERCP: a single-centre, retrospective study of influencing factors

Journal:	<i>Scandinavian Journal of Gastroenterology</i>
Manuscript ID	Draft
Manuscript Type:	Original Article
Date Submitted by the Author:	n/a
Complete List of Authors:	Saukko, Ekaterina; TYKS, The medical imaging centre of southwest Finland Grönroos, Juha; TYKS, Division of Digestive Surgery and Urology Salminen, Paulina; TYKS, Division of Digestive Surgery and Urology Henner, Anja; Oulun Seudun Ammattikorkeakoulu, School of Health and Social Care Nieminen, Miika T.; Oulun yliopistollinen sairaala, Department of Diagnostic Radiology
Keyword:	ERCP

SCHOLARONE™
Manuscripts

1
2
3 **Patient radiation dose and fluoroscopy time during ERCP: a single-**
4 **centre, retrospective study of influencing factors**
5

6
7 Ekaterina Saukko, MSc ¹, Juha M. Grönroos, MD, PhD ^{2,3}, Paulina
8 Salminen, MD, PhD ^{2,3}, Anja Henner, PhD ⁴, Miika T. Nieminen, PhD ^{5,6,7}
9

10
11
12 ¹ *The Medical Imaging Centre of Southwest Finland, Turku University Hospital,*
13 *Kiinamyllynkatu 4-8, PO Box 52, 20521 Turku, Finland*
14

15
16 ² *Division of Digestive Surgery and Urology, Turku University Hospital,*
17 *Kiinamyllynkatu 4-8, PO Box 52, 20521 Turku, Finland*
18

19
20 ³ *Department of Surgery, University of Turku, Kiinamyllynkatu 10, 20520 Turku,*
21 *Finland*
22

23
24 ⁴ *School of Health and Social Care, Oulu University of Applied Sciences, Kiviharjuntie*
25 *4, 90220 Oulu, Finland*
26

27
28 ⁵ *Research Unit of Medical Imaging, Physics and Technology, University of Oulu, PO*
29 *Box 5000, 90014 Oulu, Finland*
30

31
32 ⁶ *Department of Diagnostic Radiology, Oulu University Hospital, PO Box 50, 90029*
33 *Oulu, Finland*
34

35
36 ⁷ *Medical Research Center Oulu, University of Oulu and Oulu University Hospital, PO*
37 *Box 5000, 90014 Oulu, Finland*
38

39
40
41 Correspondence: Ekaterina Saukko, The Medical Imaging Centre of Southwest Finland,
42 Turku University Hospital, Kiinamyllynkatu 4-8, PO Box 52, 20521 Turku, Finland.

43
44 Telephone: +35823130645. E-mail: ekaterina.saukko@tyks.fi
45

46
47 Telephone numbers and email addresses of other authors: Juha M. Grönroos, +35823131234,
48 juha.gronroos@tyks.fi; Paulina Salminen, +35823130542, paulina.salminen@tyks.fi; Anja
49 Henner, +358503670361, anja.henner@oamk.fi; Miika T. Nieminen, +35883152462,
50 miika.nieminen@oulu.fi
51
52
53
54
55
56
57
58
59
60

1
2
3 Ekaterina Saukko, RT, MSc, is a Research Coordinator at Turku University Hospital and PhD
4 student at University of Oulu Graduate School, Finland. Her current research focuses on
5 optimisation of radiation protection of the patients during ERCP. Juha Grönroos is Professor of
6 Gastroenterological Surgery at University of Turku and Chief Surgeon at Division of
7 Gastroenterological Surgery and Urology. His main research topics include mini-invasive
8 surgery such as endoscopic pancreatobiliary surgery as well as infectious and inflammatory
9 diseases such as acute appendicitis and acute pancreatitis. Paulina Salminen, MD, PhD, is a
10 senior specialist in digestive surgery working at Turku University Hospital. Her main research
11 topics are acute appendicitis and bariatric surgery. Anja Henner, PhD, Principal lecturer is
12 responsible for the R&D in the Degree program of Radiography and Radiotherapy in Oulu
13 University of Applied Sciences (OUAS) since year 1998. Her research and development
14 interests are in radiation protection and digital imaging including quality assurance. Miika T.
15 Nieminen, PhD, is Professor of Medical Physics at University of Oulu and Chief Physicist at
16 Oulu University Hospital, Finland. His research interests include development of MRI and x-ray
17 based imaging methods for tissue characterisation, and radiation protection. He is Fellow of
18 International Society for Magnetic Resonance in Medicine.
19
20
21
22
23
24
25
26
27
28
29

30 A word count of manuscript: abstract 249 words, main text 3750 words
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Patient radiation dose and fluoroscopy time during ERCP: a single-centre, retrospective study of influencing factors

Objectives Recently, both the number and the complexity with associated increased technical difficulty of therapeutic ERCP procedures have significantly increased resulting in longer procedural and fluoroscopy times. During ERCP, the patient is exposed to ionizing radiation and the consequent radiation dose depends on multiple factors. The aim of this study was to identify factors affecting fluoroscopy time and radiation dose in patients undergoing ERCP.

Materials and methods Data related to patient demographics, procedural characteristics and radiation exposure in ERCP procedures (n=638) performed between August 2013 and August 2015 was retrospectively reviewed and analysed. Statistically significant factors identified by univariate analyses were included in multivariate analysis with fluoroscopy time (FT) and dose area product (DAP) as dependent variables. Effective dose (ED) was estimated from DAP measurements using conversion coefficient. **Results** The factors independently associated with increased DAP during ERCP were age, gender, radiographer, complexity level of ERCP, cannulation difficulty grade, bile duct injury and biliary stent placement. In multivariate analysis the endoscopist, the complexity level of ERCP, cannulation difficulty grade, pancreatic duct leakage, bile duct dilatation and brushing were identified as predictors for a longer FT. The mean DAP, FT, number of acquired images and ED for all ERCP procedures were 2.33 Gy·cm², 1.84 min, 3 and 0.61 mSv, respectively. **Conclusions** Multiple factors had an effect on DAP and FT in ERCP. The awareness of these factors may help to predict possible prolonged procedures causing a higher radiation dose to the patient and thus facilitate the use of appropriate precautions.

Keywords: cholangiopancreatography, endoscopic retrograde; radiation exposure; radiation protection; fluoroscopy; multivariate analysis

Introduction

Endoscopic retrograde cholangiopancreatography (ERCP), used as a gold standard in the endoscopic treatment of pancreatobiliary disorders, continues to be one of the most complex and technically demanding gastrointestinal procedures [1-3]. This invasive

1
2
3 procedure requires the use of fluoroscopy and therefore places both the patient and the
4
5 endoscopy staff at risk of radiation-induced injury [4]. Risks associated with ionizing
6
7 radiation include cataract, infertility, skin injury, hair loss, malignancy, and genetic
8
9 effects [5].
10

11 During ERCP, the patient is exposed to the primary beam and consequently
12
13 receives a higher radiation dose compared to endoscopy staff, whose major source of
14
15 radiation exposure is caused by scattered radiation from the patient [6]. Over the years,
16
17 both the number and the complexity with associated increased technical difficulty of
18
19 therapeutic ERCP procedures have significantly increased resulting in longer procedural
20
21 [7] and fluoroscopy times [8, 9]. Prolonged fluoroscopy time to the same skin area,
22
23 irradiation through thick body masses as well as an extensive use of high-dose rate
24
25 modes may produce a high radiation dose to the patient's skin and increase the risk of
26
27 radiation-induced skin injury [10, 11]. Skin injury may occur if the skin dose exceeds a
28
29 threshold dose of 2 Grey (Gy) for transient erythema [12]. Grey (Gy) is a unit of
30
31 absorbed radiation dose, defined as 1 joule of energy deposited in 1 kilogram of mass (1
32
33 J/kg). According to International Commission on Radiological Protection (ICRP),
34
35 ERCP procedure has the potential to impart skin doses exceeding 1 Gy [13].
36
37
38

39 In order to understand both the optimization of the radiation exposure in
40
41 fluoroscopy procedures and minimizing the risk of radiation-induced injury, it is
42
43 essential to be familiar with the factors influencing patient radiation dose [1, 6, 11].
44
45 Previously, it has been found that the type of x-ray unit, anatomical location of
46
47 pathology, difficult cannulation, annual volume and experience of endoscopist, trainee
48
49 involvement, complexity of procedure, sphincterotomy, stent insertion, balloon
50
51 dilatation, stone extraction, and other interventions influenced on the exposure levels in
52
53 ERCP [8, 9, 14-22]. A randomized trial by Uradomo et al. [22] showed that a
54
55
56
57
58
59
60

1
2 behavioural intervention (time limiting the fluoroscopy to 3 seconds each time the foot-
3 operated switch is depressed) was associated with a 16 % lower fluoroscopy time.

4
5
6
7 Decreasing the distance between the endoscopy and fluoroscopy screens in the ERCP
8
9 was also found to reduce a fluoroscopy time by 1.4 minutes [23].
10

11
12 Although several studies have been performed to identify factors associated with
13 prolonged fluoroscopy time and increased radiation exposure in ERCP, these have not
14 been completely clarified [19] and the impact of difficulty degree of ERCP procedure
15 on patient radiation dose remains unclear. The aim of the present study was to
16 determine factors affecting fluoroscopy time and radiation dose in patients undergoing
17 ERCP in a single tertiary care hospital performing some 450-500 ERCPs annually.
18
19
20
21
22
23
24
25

26 **Materials and methods**

27
28 This study is a retrospective data review covering prospective data collection in an
29 already running database, previously initiated for quality control and for scientific
30 purposes in the endoscopy unit at Turku University Hospital, Finland. The database
31 comprises data from ERCP including patients' demographics, indications for ERCP,
32 cannulation time and cannulation methods, performed interventions and used
33 techniques, post-ERCP diagnosis, total procedural time and the endoscopist. Similarly,
34 the specific reason for possible unsuccessful procedure was registered. All consecutive
35 patients undergoing ERCP between August 2013 and August 2015 were enrolled in this
36 study.
37
38
39
40
41
42
43
44
45
46

47
48 The data of included consecutive ERCP patients (n=756) was complemented by
49 radiation quantities, such as dose area product (DAP, Gy·cm²), fluoroscopy time (FT,
50 min) and the number of radiographic images that were retrieved directly from
51 Radiology Information System (RIS) and Picture Archiving and Communication
52 System (PACS). DAP is a product of the air kerma (Gy) and exposed area of the skin
53
54
55
56
57
58
59
60

1
2
3 (m²) providing a good estimation of the total radiation energy delivered to the patient
4 during a procedure [15, 24]. Effective dose (ED) is an indicator of the risk for stochastic
5 effects (cancer, genetic effects) [25] and ED (measured in Sieverts, Sv) was estimated
6 from DAP measurements by a conversion coefficient of 0.26 mSv/(Gy·cm²) [26]. ED
7 allows a comparison across different radiological procedures and various hospitals [25].
8
9
10
11
12

13 Based on clinical guideline from European Society of Gastrointestinal
14 Endoscopy (ESGE), the cannulation in ERCP was considered being difficult if more
15 than 5 minutes was spent attempting to cannulate following visualization of the papilla
16 [27]. The cannulation difficulty was graded according to the time needed to achieve a
17 successful selective deep cannulation as follows: <1 min (1=easy), 1-5 min
18 (2=intermediate), >5 min (3=difficult). The cannulation time was measured by an
19 assisting radiographer and counted from the first touch to papilla to a successful
20 cannulation of the desired duct. Procedural complexity of ERCP was determined using
21 the grading system proposed by the working group of the American Society for
22 Gastrointestinal Endoscopy (ASGE) Quality Committee with scores ranging from 1
23 (simple ERCP) to 4 (the most complex ERCPs) based on clinical context and performed
24 interventions [28]. The grades are defined as follows: grade 1 (biliary stent removal or
25 exchange, brushing), grade 2 (biliary stone extraction <10 mm, treating biliary leaks,
26 treating extrahepatic benign and malignant strictures), grade 3 (biliary stone extraction
27 >10 mm, minor papilla cannulation, removing of internally migrated biliary stents,
28 management of acute or recurrent pancreatitis, treating pancreatic strictures, removing
29 mobile pancreatic stones and stones <5 mm, treating benign strictures in hilum and
30 above) and grade 4 (removing internally migrated pancreatic stents, removing impacted
31 pancreatic stones and stones >5 mm, intrahepatic stones, pseudocyst drainage,
32 ampullectomy). Because of the small number of ERCP procedures of 4th degree
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 appears in this data (n=5), the complexity grades 3 and 4 were combined into one
4
5 group.

6
7 All ERCP procedures were performed for clinical symptoms or for pathologic
8
9 findings detected in other examinations. Five experienced endoscopists performed the
10
11 procedures and those performed by a trainee were excluded from the study. Patients
12
13 were positioned on the left side for the ERCP and procedures were completed under
14
15 conscious sedation with midazolam and fentanyl administered by a nurse according to
16
17 the instructions of the endoscopist. During ERCP, the fluoroscopy was operated by the
18
19 endoscopist while fluoroscopy system was controlled by a radiographer. The same
20
21 fluoroscopic system (MultiDiagnost Eleva, Philips Medical Systems, Best, The
22
23 Netherlands) was used in ERCP throughout the study period, and it was equipped with a
24
25 multipurpose C-arm and with an image intensifier. The dose measuring device was
26
27 integrated into the equipment. During ERCP pulsed fluoroscopy with lowest possible
28
29 pulse rate of 1.5 fps was used and the x-ray beam was modified by collimating the field
30
31 size to the region of interest.
32
33

34
35 Statistical analysis was performed using the IBM SPSS Statistics for Windows,
36
37 Version 22 (IBM Corp. 2013 Armonk, NY). Failed ERCP procedures and those with
38
39 missing radiation exposure data were excluded from the final analysis. Categorical data
40
41 were presented as frequency and percentage. Continuous data were expressed as mean \pm
42
43 standard deviation (SD), range, standard error (SE) or median with interquartile range
44
45 (IQR) as indicated. Differences in continuous variables were tested using Mann-
46
47 Whitney U-test or Kruskal-Wallis test for nonparametric data. Factors associated with
48
49 increased FT and DAP in ERCP were evaluated by univariate analysis performed with a
50
51 logarithmic transformation of the DAP and FT due to asymmetric distributions.
52
53 Statistically significant variables were included in the multivariate analysis. Bonferroni
54
55
56
57
58
59
60

1
2
3 adjustments were applied for all post-hoc tests to adjust p-values for multiple
4
5 comparisons. A p value less than 0.05 was considered statistically significant.
6

7 Institutional review board approval was obtained at the Turku University
8
9 Hospital. According to Finnish Medical Research Act [29], the retrospective nature of
10
11 this study does not require the approval from local ethics committee. Data was
12
13 anonymized before statistical analysis prohibiting subsequent patient identification.
14
15

16 17 **Results**

18
19 Altogether 638 out of 756 ERCP procedures were analysed in this study to determine
20
21 factors affecting fluoroscopy time and radiation dose to patient, as the failed procedures
22
23 (n=86) and those performed by a trainee (n=27) or with missing radiation exposure data
24
25 (n=5) were excluded from the study. Common reasons for failed ERCP were
26
27 unsuccessful cannulation (n=37, 43%) and gastroduodenal obstruction (n=26, 30%).
28
29 48% of the patients were male and the mean age for all patients was 66.0 years (Table
30
31 1). The main indication for ERCP was bile duct stone removal (n=261, 41%) followed
32
33 by malignant strictures (n=100, 16%) and jaundice of unknown etiology (n=80, 13%).
34
35 Most of the ERCP procedures (n=463, 73%) were carried out in patients with native
36
37 papilla. The time needed to achieve a successful selective deep cannulation of the
38
39 desired duct was <1 min in 40%, 1-5 min in 34% and >5 min in 26% of those ERCP
40
41 cases where the time was recorded (n=537). The cannulation success rate was 95% in
42
43 patients with free access to papilla. Typical findings in ERCP were bile duct stones
44
45 (n=208, 33%), benign and malignant bile duct strictures (n=174, 27%) and normal
46
47 anatomy (n=65, 10%). [Table 1 near here]
48
49
50

51
52 The results showed a large variation in radiation quantities (Table 2). The mean
53
54 DAP, FT and number of radiographic images for all ERCP procedures were 2.33 ± 1.79
55
56 (range 0.09-14.19) Gy·cm², 1.84 ± 1.56 (range 0.11-9.57) min and 3.02 ± 1.83 (range 0-
57
58
59
60

1
2
3 11), respectively. A positive linear correlation was observed between DAP and FT
4 (rs=0.73, $p < 0.01$), as well as between DAP and the number of radiographic images
5 (rs=0.52, $p < 0.01$). The average ED of the ERCP patient was 0.61 ± 0.47 (range 0.02-
6 3.69) mSv. Male gender was associated with a greater radiation exposure (2.55 ± 1.92
7 Gy·cm²) compared to females (2.11 ± 1.65 Gy·cm²) and the difference was statistically
8 significant ($p=0.001$). Patients who underwent ERCP for the first time received a lower
9 radiation dose (2.21 ± 1.67 Gy·cm²) than those who had repeat ERCP (2.63 ± 2.06
10 Gy·cm²) procedure ($p=0.036$). FT was also significantly longer in the repeat ERCP than
11 in the primary one ($p=0.024$). Moreover, patients with suspected ($p<0.001$) or
12 diagnosed ($p=0.01$) bile duct injury had a higher radiation dose than those with bile duct
13 stones. Similarly, post-ERCP diagnosis of pancreatic duct leakage was associated with a
14 higher DAP ($p<0.001$) and longer FT ($p=0.03$). Increased image acquisition during
15 ERCP was noted in patients with bile duct stricture ($p<0.001$) and bile duct injury
16 ($p<0.001$). The mean of acquired images was also high in patients with pancreatic duct
17 leakage ($n=12$), but statistical significance was not reached. [Table 2 near here]

18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35 The difficult cannulation with cannulation time exceeding 5 min was related to
36 increased DAP and prolonged FT compared to those ERCP procedures with cannulation
37 lasting between 1 and 5 min (DAP $p=0.012$; FT $p < 0.001$) or being under 1 min (DAP
38 $p=0.004$; FT $p<0.001$). Based on ERCP complexity grading system, the majority (60%)
39 of performed ERCP procedures in this study were of complexity grade 2 (Table 2). The
40 grade 1 procedures constituted 20% and grade 3 and 4 combined were 21%. There was
41 a significant difference in DAP between the ERCP complexity grades 1 and 3 ($p=0.004$)
42 as well as between grades 2 and 3 ($p<0.001$). The same statistical difference was noted
43 in FT for complexity grade 1 versus grade 3 ($p<0.001$) and complexity grade 2 versus 3
44 ($p<0.001$). The mean DAP (2.84 ± 1.85 Gy·cm²) and FT (2.45 ± 1.71 min) were highest
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 in procedures of 3rd grade (Table 2). However, the mean DAP and FT did not increase
4
5 in concert with the increase in complexity scale.
6

7 Three out of five endoscopists performed higher number of ERCP procedures of
8
9 3rd grade complexity and difference in relative proportion of difficult procedures was
10
11 also observed between the endoscopists (Table 3). The mean FT was substantially
12
13 longer in ERCP procedures performed by endoscopist 1 (2.11 ± 1.87 min, $p < 0.001$), 3
14
15 (1.81 ± 1.40 min, $p < 0.001$), 4 (1.79 ± 1.58 min, $p < 0.001$) and 5 (2.25 ± 1.27 min, $p < 0.001$)
16
17 compared with endoscopist 2 (0.92 ± 0.91 min). Regarding DAP, the differences between
18
19 endoscopists did not reach the statistical significance. There were no significant
20
21 differences in image acquisition between endoscopists either. In addition, it was found
22
23 that DAP varied in ERCP depending on who of the ten radiographers was controlling
24
25 the fluoroscopy system ($p < 0.001$). The highest mean DAP was 4.06 ± 2.31 Gy·cm² in
26
27 procedures with involvement of radiographer 6. Nevertheless, there were no significant
28
29 differences among radiographers in FT or procedural complexity of performed ERCP
30
31 procedures (Fig. 1). [Table 3 near here] [Figure 1 near here]
32
33
34

35 The univariate and multivariate analysis with log-transformed data identified
36
37 several factors as predictors for higher DAP (Table 4) and prolonged FT (Table 5) in
38
39 ERCP. In univariate analysis, the variables that were found to be significantly
40
41 associated with both radiation quantities were complexity level of ERCP, cannulation
42
43 difficulty grade, bile duct stricture, bile duct injury and pancreatic duct leakage. Age,
44
45 gender, radiographer involved in ERCP, jaundice and suspicion of bile duct injury were
46
47 associated statistically only with DAP, whereas endoscopist performing ERCP was
48
49 related only to FT. Multivariate modelling performed with DAP as dependent variable
50
51 showed that clinical indication and post-ERCP-diagnosis were highly correlated, if
52
53 included in the same model. Based on this, the indication was excluded from the final
54
55
56
57
58
59
60

1
2
3 analysis. In addition, the types of interventions performed during ERCP were included
4 directly in multivariate analysis. To assess the independent effect of certain variables on
5 DAP and FT, a total of 3 models were selected in multivariate analysis for both
6
7 dependent variables.
8
9

10
11 Multivariate analysis showed that gender (female vs male), age (<35 vs 36-65
12 years), radiographer (1 vs 2, 4, 5, 6, 9, 10), complexity level of ERCP (grade 2 vs 3) and
13 cannulation difficulty grade (in all comparisons) were independently associated with
14 increased DAP in all selected models (Table 4). Post-ERCP diagnoses such as bile duct
15 stricture ($p<0.001$), cholangitis ($p=0.01$), bile duct injury ($p<0.001$) and other ($p=0.03$)
16 were found to be associated with a higher DAP in the multivariate model 1, but when
17 interventions were included in the model (model 2), only bile duct injury ($p<0.001$)
18 remained significant. The biliary stent placement was the only intervention performed
19 during ERCP that independently predicted a higher DAP.
20
21

22
23 Similarly, factors independently related to prolong FT (Table 5) in all selected
24 models of multivariate analysis were endoscopist (in all comparisons), complexity level
25 of ERCP (grade 2 vs 3) and cannulation difficulty grade (in all comparisons). Post-
26 ERCP diagnoses such as bile duct stricture ($p=0.03$), cholangitis ($p=0.04$), bile duct
27 injury ($p<0.001$) and pancreatic duct leakage ($p=0.02$) were associated with longer FT
28 in multivariate model (model 1), but when interventions were included in the model
29 (model 2), only pancreatic duct leakage ($p=0.03$) remained significant. Interventions
30 like bile duct dilatation and brushing were identified by multivariate analysis as
31 predictors for longer FT. Furthermore, the multivariate analysis revealed that biliary
32 stent placement was also associated with longer FT, when the diagnosis was removed
33 from the model (model 3). [Table 4 near here] [Table 5 near here]
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Discussion

In recent years, there has been a growing interest generated by research in the field of radiation exposure of both the patient and medical staff during ERCP procedures, as it has been recognized that ERCP requires the same level of radiation protection practice as all other interventional radiological procedures [1, 3, 4, 6, 8, 9, 14-23, 30-37]. This study was performed to identify factors associated with FT and radiation dose measured by DAP in patients undergoing ERCP in a single tertiary care hospital. The factors independently associated with increased DAP during ERCP were gender, age, radiographer, complexity level of ERCP, cannulation difficulty grade, bile duct injury and biliary stent placement. Endoscopist, complexity level of ERCP, cannulation difficulty grade, pancreatic duct leakage, bile duct dilatation and brushing were identified by multivariate analysis as predictors for longer FT. The mean DAP, FT, number of acquired images and ED for all ERCP procedures were 2.33 Gy·cm², 1.84 min, 3 and 0.61 mSv, respectively. Assuming a linear response at low doses, the combined detriment from stochastic effects has remained unchanged at around 5% per Sievert [25] and it follows that the lifetime cancer risk from ERCP is approximately 0.003%.

Previous studies investigating factors related to increased radiation exposure in patients during ERCP have been focused mainly on FT [8, 17, 19-21, 23, 37], only some studies have included DAP in the analysis [9, 15, 18, 38]. There is a good correlation between FT and DAP in ERCP according to the literature [30, 32, 34-36, 38], however in some studies a correlation was not found [4, 39]. FT is one of the features that determine radiation exposure, but as a surrogate measure, FT is not sufficient in monitoring patient radiation doses since it has several limitations [34, 40, 41]. For instance, some factors affecting DAP are not included in FT, such as patient

1
2
3 size and position, imaging geometry, settings of the fluoroscopy equipment,
4
5 collimation, magnification, angulation, acquisition images and filtration [20, 33, 34, 42].
6
7 The results of the present study also revealed that variables associated with increased
8
9 DAP and prolonged FT in ERCP were partly different.

10
11 Male gender was associated with a higher DAP, likely attributable to the larger
12
13 size of male patients. Larger patient size requires a higher radiation dose to obtain
14
15 adequate image quality than the normal-sized patient [43]. Unfortunately, body weights
16
17 of the patients were not registered at the time when original data was collected, as this
18
19 information could have been provided an additional benefit for this study. Younger
20
21 patients, i.e. under 35 years, received a lower radiation dose than the patients between
22
23 36 and 65 years, probably owing to simpler ERCP procedures performed in that age
24
25 group and for better dose optimisation practice. In a previous study by Rodríguez-
26
27 Perálvarez et al. [38] an independent association was observed between younger
28
29 patients and a higher DAP in ERCP, however, the authors did not identify any logical
30
31 explanation for it. It is essential to pay a special attention to the radiation protection of
32
33 young patient, but as life expectancy increases, highlighting the benefits of radiation
34
35 protection in the elderly is also important [44].
36
37
38

39
40 The observed significant differences in FT between endoscopists were likely
41
42 related to procedural complexity in ERCP, as endoscopists who performed more ERCPs
43
44 with a greater procedural complexity had a longer FT on average. There seemed to be
45
46 differences in DAP among endoscopists as well, but they did not reach the statistical
47
48 significance in this study. Differences in training, experience and individual practice
49
50 patterns of endoscopists could also explain these variations in FT and DAP [37].
51
52 Previous studies have demonstrated that ERCP volume of endoscopist fewer than 200
53
54 procedures in the preceding year has been associated with a longer FT [20] and
55
56
57
58
59
60

1
2
3 increased DAP [15]. In addition, an involvement of a trainee in ERCP procedures has
4
5 been noticed to associate with increase in FT [16, 17, 20, 21]. The differences in DAP
6
7 among radiographers are likely the result of different collimation practices during
8
9 ERCP, since significant differences in FT or procedural complexity of performed
10
11 procedures were not found. This association has not been reported previously. Even
12
13 though a fluoroscopy system includes multiple settings that can be adjusted during
14
15 ERCP, radiographers at our institution typically modify only the collimation.
16
17 Collimation of the irradiated surface area to the region of interest is important, because
18
19 it reduces the radiation exposure of the patient and improves image quality by limiting
20
21 the amount of scattered radiation to the detector [45].
22
23

24 Bile duct injury was found to have a significant impact on DAP, which probably
25
26 is related to increase in use of image acquisition during ERCP as high image quality is
27
28 needed to visualize fine details and subtle contrast differences in the anatomy of
29
30 interest. FT was also longer for patients with bile duct injury, likely due to additional
31
32 interventions performed during ERCP, such as sphincterotomy and stent placement.
33
34 This difference reached the statistical significance in univariate analysis and in one of
35
36 the multivariate models. The same effect on DAP and FT was observed with diagnosis
37
38 of pancreatic duct leakage, though association with FT was stronger. Multivariate
39
40 analysis revealed that interventions such as bile duct dilatation and brushing predicted a
41
42 longer FT in ERCP. Biliary stent placement was significantly related to higher DAP and
43
44 an association between biliary stent placement and FT was also found in one of the
45
46 multivariate models. All these significant variables have already been reported
47
48 previously [8, 17-19, 21, 23, 37, 46] and without a doubt these interventions require
49
50 fluoroscopy to confirm proper placement of instruments and to assist in the endoscopic
51
52 therapy. The use of balloon catheter as a dilatator is often followed by cholangiogram,
53
54
55
56
57
58
59
60

1
2
3 consequently requiring longer FT. One possible reason for the stronger association of
4
5 the biliary stent placement with the DAP instead of FT is that the outcome of stent
6
7 insertion is usually documented at our hospital by image acquisition.
8

9
10 Difficult and complex procedures typically take more time, require prolonged
11
12 fluoroscopy time and therefore associate with a higher radiation dose [47]. Complexity
13
14 level of ERCP and cannulation difficulty grade were both independently associated with
15
16 a higher DAP and longer FT in present study. It seems that cannulation difficulty is a
17
18 better predictor of the increase in DAP and FT than the grading system of ERCP
19
20 complexity. Performed interventions during ERCP were somewhat associated with the
21
22 complexity level of ERCP, since significant differences in DAP and FT were observed
23
24 only between the complexity grades 2 and 3 (multivariate models 2 and 3). ASGE [28]
25
26 complexity grading system was originally developed for a method of evaluating
27
28 outcomes/adverse events based on the degree of procedural difficulty. In addition, this
29
30 grading system does not take into consideration the number of interventions performed
31
32 or the number of instruments used during ERCP as these both has been found to be
33
34 significant and have an effect on FT [37]. Recently, a new “HOUSE” -grading scale for
35
36 ERCP complexity was developed by Olsson et al. [48], which classified procedures into
37
38 three classes in line with the modern endoscopic treatment procedures in ERCP.
39
40

41
42 In conclusion, multiple factors were found to affect DAP and FT in ERCP. The
43
44 awareness of these factors may help to predict possible prolonged procedures causing a
45
46 higher radiation dose to the patient and thus facilitate the use of appropriate precautions.
47
48 This is particularly important in the complex cases, as difficult papillary cannulation
49
50 and complexity level of ERCP were both independently associated with a higher DAP
51
52 and longer FT. Minimizing patient radiation dose in ERCP remains an essential goal in
53
54 the optimisation process and the endoscopist has the most significant role in the amount
55
56
57
58
59
60

1
2
3 of fluoroscopy time used during ERCP. Optimization of patient exposure will
4
5 consequently improve the radiation protection of the staff involved in ERCP
6
7 procedures. A good radiation protection practice can be achieved through continuing
8
9 education and training of medical staff as well as by ensuring quality of fluoroscopy
10
11 equipment.
12

13
14
15
16
17 **Disclosure of interest** Paulina Salminen has received lecture fees from Merck and Lilly.
18
19 The remaining authors declare that they have no conflicts of interest.
20
21
22
23

24 25 **References**

- 26 1. Kachaamy TA, Faigel DO. Improving ERCP quality and decreasing risk to patients
27 and providers. *Expert Rev Gastroenterol Hepatol.* 2013;7:531-540.
- 28 2. Grönroos JM. Clinical success of ERCP procedures in nonagenarian patients with
29 bile duct stones. *Minim Invasive Ther Allied Technol.* 2011;20:146-149.
- 30 3. Boix J, Lorenzo-Zúniga V. Radiation dose to patients during endoscopic retrograde
31 cholangiopancreatography. *World J Gastrointest Endosc.* 2011;3:140-144.
- 32 4. Tsapaki V, Paraskeva KD, Mathou N, et al. Patient and endoscopist radiation doses
33 during ERCP procedures. *Radiat Prot Dosim.* 2011;147:111-113.
- 34 5. United Nations Scientific Committee on the Effects of Atomic Radiation. Sources,
35 Effects and Risks of Ionizing Radiation. UNSCEAR 2012 Report. Report to the
36 General Assembly with Scientific Annexes. United Nations publication sales
37 E.16.IX.1. NY: United Nations; 2015.
- 38 6. Amis ES Jr. Risk of radiation exposure in the endoscopy suite: principles, cautions,
39 and risks to patient and endoscopy staff. *Tech Gastrointest Endosc.* 2007;9:213-
40 217.
- 41 7. Mehta PP, Sanaka MR, Parsi MA, et al. Association of procedure length on outcomes
42 and adverse events of endoscopic retrograde cholangiopancreatography.
43 *Gastroenterol Rep (Oxf).* 2014;2:140-144.
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3 8. Alkhatib AA, Abdel Jalil AA, Faigel DO, et al. Anatomical location of pathology is
4 predictive of prolonged fluoroscopy time during ERCP: a multicenter American
5 study. *Dig Dis Sci*. 2015;60:1787-1792.
6
- 7
8 9. Churrango G, Deutsch JK, Dinneen HS, et al. Minimizing radiation exposure during
9 ERCP by avoiding live or continuous fluoroscopy. *J Clin Gastroenterol*.
10 2015;49:e96-100.
11
- 12
13 10. Wagner LK. Radiation injury is a potentially serious complication to
14 fluoroscopically-guided complex interventions. *Biomed Imaging Interv J*.
15 2007;3:e22.
16
- 17
18 11. Killewich LA, Falls G, Mastracci TM, et al. Factors affecting radiation injury. *J*
19 *Vasc Surg*. 2011;53:9S-14S.
20
- 21
22 12. Balter S, Hopewell JW, Miller DL, et al. Fluoroscopically guided interventional
23 procedures: a review of radiation effects on patients' skin and hair. *Radiology*.
24 2010;254:326-341.
25
- 26
27 13. International Commission on Radiological Protection. Radiological protection in
28 fluoroscopically guided procedures outside the imaging department. ICRP
29 Publication 117. *Ann ICRP*. 2010;40:1-102.
30
- 31
32 14. Tsapaki V, Paraskeva KD, Tsalafoutas IA, et al. The impact of x-ray unit type used
33 for endoscopic retrograde cholangiopancreatography procedures on patient
34 doses. *Radiat Prot Dosimetry*. 2016;171:503-508.
35
- 36
37 15. Liao C, Thosani N, Kothari S, et al. Radiation exposure to patients during ERCP is
38 significantly higher with low-volume endoscopists. *Gastrointest Endosc*.
39 2015;81:391-398.
40
- 41
42 16. Oztas E, Parlak E, Kucukay F, et al. The impact of endoscopic retrograde
43 cholangiopancreatography education on radiation exposure to experienced
44 endoscopist: 'trainee effect'. *Dig Dis Sci*. 2012;57:1134-1143.
45
- 46
47 17. Kim E, McLoughlin M, Lam EC, et al. Prospective analysis of fluoroscopy duration
48 during ERCP: critical determinants. *Gastrointest Endosc*. 2010;72:50-57.
49
- 50
51 18. Lorenzo-Zúñiga V, Alvarez MA, Moreno de Vega V, et al. Predictive factors of
52 radiation dose in ERCP: a prospective study in 2 tertiary centers. *Surg Laparosc*
53 *Endosc Percutan Tech*. 2013;23:266-270.
54
- 55
56 19. Katsinelos P, Gatopoulou A, Gkagkalis S, et al. A prospective analysis of factors
57 influencing fluoroscopy time during therapeutic ERCP. *Ann Gastroenterol*.
58 2012;25:338-344.
59
60

- 1
2
3 20. Jorgensen JE, Rubenstein JH, Goodsitt MM, et al. Radiation doses to ERCP patients
4 are significantly lower with experienced endoscopists. *Gastrointest Endosc.*
5 2010;72:58-65.
6
- 7 21. Romagnuolo J, Cotton PB. Recording ERCP fluoroscopy metrics using a
8 multinational quality network: establishing benchmarks and examining time-
9 related improvements. *Am J Gastroenterol.* 2013;108:1224-1230.
10
- 11 22. Uradomo LT, Goldberg EM, Darwin PE. Time-limited fluoroscopy to reduce
12 radiation exposure during ERCP: a prospective randomized trial. *Gastrointest*
13 *Endosc.* 2007;66:84-89.
14
- 15 23. Jowhari F, Hopman WM, Hookey L. A simple ergonomic measure reduces
16 fluoroscopy time during ERCP: A multivariate analysis. *Endosc Int Open.*
17 2017;5:E172-E178.
18
- 19 24. International Commission on Radiation Units and Measurements. Patient dosimetry
20 for x rays used in medical imaging. Report 74. *J ICRU.* 2005;5: 1-113.
21
- 22 25. International Commission on Radiological Protection. The 2007 recommendations
23 of the International Commission on Radiological Protection. ICRP publication
24 103. *Ann ICRP.* 2007;37: 1-332.
25
- 26 26. National Council on Radiation Protection and Measurements. Ionizing radiation
27 exposure of the population of the United States. NCRP Report 160. Bethesda,
28 MD; 2009.
29
- 30 27. Testoni PA, Mariani A, Aabakken L, et al. Papillary cannulation and
31 sphincterotomy techniques at ERCP: European Society of Gastrointestinal
32 Endoscopy (ESGE) Clinical Guideline. *Endoscopy.* 2016;48:657-683.
33
- 34 28. Cotton PB, Eisen G, Romagnuolo J, et al. Grading the complexity of endoscopic
35 procedures: results of an ASGE working party. *Gastrointest Endosc.*
36 2011;73:868-874.
37
- 38 29. Laki lääketieteellisestä tutkimuksesta 488/1999 [Medical Research Act No.
39 488/1999]. 1999 Nov 1 [cited 2017 Oct 20]. Available from:
40 <https://www.finlex.fi/fi/laki/ajantasa/1999/19990488>. Finnish.
41
- 42 30. Seo D, Kim KH, Kim JS, et al. Evaluation of radiation doses in patient and medical
43 staff during endoscopic retrograde cholangiopancreatography procedures. *Radiat*
44 *Prot Dosimetry.* 2016;168:516-522.
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3 31. Sulieman A, Elzaki M, Alkhorayef M, et al. Assessment of patient dose and
4 radiogenic risks during endoscopic retrograde cholangiopancreatography. *Appl*
5 *Radiat Isot.* 2016;117:65-69.
6
- 7 32. Hadjiconstanti AC, Messaris GA, Thomopoulos KC, et al. Patient dose during
8 therapeutic endoscopic retrograde cholangiopancreatography procedure. *Radiat*
9 *Prot Dosimetry.* 2017;173:380-382.
10
- 11 33. Tsapaki V, Paraskeva DK, Giannakopoulos A, et al. Patient and Staff Radiation
12 Exposure during Endoscopic Retrograde Cholangio-Pancreatography: Eight
13 Years of Dose Monitoring. *OMICS J Radiol.* 2017;6:253.
14
- 15 34. Kachaamy T, Harrison E, Pannala R, et al. Measures of patient radiation exposure
16 during endoscopic retrograde cholangiography: Beyond fluoroscopy time.
17 *World J Gastroenterol.* 2015;21:1900-1906.
18
- 19 35. Saukko E, Henner A, Ahonen SM. Radiation exposure to patients during endoscopic
20 retrograde cholangiopancreatography: A multicentre study in Finland.
21 *Radiography.* 2015;21:131-135.
22
- 23 36. Saukko E, Henner A, Nieminen MT, et al. The establishment of local diagnostic
24 reference levels in endoscopic retrograde cholangiopancreatography: a practical
25 tool for the optimization and quality assurance management. *Radiat Prot*
26 *Dosimetry.* 2017;173:338-344.
27
- 28 37. Kim E, McLoughlin M, Lam EC, et al. Retrospective analysis of radiation exposure
29 during endoscopic retrograde cholangiopancreatography: critical determinants.
30 *Can J Gastroenterol.* 2011;25:555-559.
31
- 32 38. Rodríguez-Perálvarez ML, Miñano-Herrero JA, Hervás-Molina AJ, et al. Radio
33 induced cancer risk during ERCP. Is it a real clinical problem? *Rev Esp Enferm*
34 *Dig.* 2011;103:191-195.
35
- 36 39. Brambilla M, Marano G, Dominietto M, et al. Patient radiation doses and references
37 levels in interventional radiology. *Radiol Med.* 2004;107:408-418.
38
- 39 40. Skripochnik E, Loh SA. Fluoroscopy time is not accurate as a surrogate for radiation
40 exposure. *Vascular.* 2017;25:466-471.
41
- 42 41. Ghelani SJ, Glatz AC, David S, et al. Radiation dose benchmarks during cardiac
43 catheterization for congenital heart disease in the United States. *JACC*
44 *Cardiovasc Interv.* 2014;7:1060-1069.
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3 42. Dumonceau JM, Garcia-Fernandez FJ, Verdun FR, et al. Radiation protection in
4 digestive endoscopy: European Society of Digestive Endoscopy (ESGE)
5 guideline. *Endoscopy*. 2012;44:408-421.
6
7 43. Yanch JC, Behrman RH, Hendricks MJ, et al. Increased radiation dose to
8 overweight and obese patients from radiographic examinations. *Radiology*.
9 2009;252:128-139.
10
11 44. Hernández L, Terradas M, Camps J, et al. Aging and radiation: bad companions.
12 *Aging Cell*. 2015;14:153-161.
13
14 45. Walters TE, Kistler PM, Morton JB, et al. Impact of collimation on radiation
15 exposure during interventional electrophysiology. *Europace*. 2012;14:1670-
16 1673.
17
18 46. Kruit AS, Vleggaar FP, van Erpecum KJ, et al. No reduction of radiation dose
19 following the introduction of dose-area product measurement in endoscopic
20 retrograde cholangiopancreatography. *Eur J Gastroenterol Hepatol*.
21 2015;27:1454-1458.
22
23 47. World Gastroenterology Organisation. Radiation protection in the endoscopy suite.
24 Minimizing radiation exposure for patients and staff in endoscopy: a joint
25 ASGE/IAEA/WGO guideline. 2009 [cited 2017 Oct 20]. Available from:
26 [http://www.worldgastroenterology.org/guidelines/global-guidelines/radiation-
27 protection-in-the-endoscopy-suite/radiation-protection-in-the-endoscopy-suite-
28 english](http://www.worldgastroenterology.org/guidelines/global-guidelines/radiation-protection-in-the-endoscopy-suite/radiation-protection-in-the-endoscopy-suite-english)
29
30 48. Olsson G, Arnelo U, Swahn F, et al. The H.O.U.S.E. classification: a novel
31 endoscopic retrograde cholangiopancreatography (ERCP) complexity grading
32 scale. *BMC Gastroenterol*. 2017;17:38.
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Table 1 Patient demographics and procedural characteristics of 638 ERCP procedures

Variables	Total
Gender [n (%)]	
Female	330 (51.7)
Male	308 (48.3)
Age (y) [mean±SD]	66.0 ± 16.7
Indication [n (%)]	
Bile duct stones	261 (40.9)
Malignant strictures	100 (15.7)
Jaundice	80 (12.5)
Cholangitis	61 (9.6)
Chronic pancreatitis	28 (4.4)
Suspicion of bile duct injury	22 (3.4)
Pseudocyst	8 (1.3)
Stent removal or exchange	36 (5.6)
Other	42 (6.6)
Type of ERCP [n (%)]	
Primary ERCP	463 (72.6)
Repeat ERCP	175 (27.4)
Total cannulation time (<i>min</i> , <i>n</i> =537) [median (IQR)]	1.67 (0.49-5.2)
Post-ERCP diagnosis [n (%)]	
Normal anatomy	65 (10.2)
Bile duct stricture	174 (27.3)
Bile duct stones	208 (32.6)
Cholangitis	48 (7.5)
Chronic pancreatitis	26 (4.1)

1		
2		
3	Pseudocyst	6 (0.9)
4		
5	Bile duct dilatation	20 (3.1)
6		
7	Bile duct injury	22 (3.4)
8		
9	Stent problems	16 (2.5)
10		
11	Pancreatic duct leakage	12 (1.9)
12		
13	Other	41 (6.4)
14		
15		
16	Types of interventions (n=1229) [n (%)]	
17	Sphincterotomy	366 (29.8)
18		
19	Biliary stone extraction	314 (25.5)
20		
21	Bile duct dilatation	135 (11.0)
22		
23	Biliary stent placement	222 (18.1)
24		
25	Biliary stent removal	70 (5.7)
26		
27	Pancreatic sphincterotomy	21 (1.7)
28		
29	Pancreatic stone extraction	3 (0.2)
30		
31	Pancreatic duct dilatation	9 (0.7)
32		
33	Pancreatic stent placement	22 (1.8)
34		
35	Pancreatic stent removal	11 (0.9)
36		
37	Brushing	34 (2.8)
38		
39	Other	22 (1.8)
40		
41		
42		
43	Total procedural time (<i>min</i> , <i>n</i> =542) [median (IQR)]	17.0 (12.0-25.0)
44		

ERCP indicates endoscopic retrograde cholangiopancreatography, SD standard deviation, IQR interquartile range

Table 2 Dose area product (DAP), fluoroscopy time (FT) and radiographic images by different variables in 638 ERCP procedures

	DAP ($Gy \cdot cm^2$)		FT (min)		Radiographic images	
	mean \pm SD	median [IQR]	mean \pm SD	median [IQR]	mean \pm SD	median (range)
Overall ($n=638$)	2.33 \pm 1.79	1.83 [1.20-2.90]	1.84 \pm 1.56	1.37 [0.90-2.30]	3.02 \pm 1.83	3.0 (0-11)
Gender						
Female ($n=330$)	2.11 \pm 1.65	1.68 [1.12-2.60]	1.87 \pm 1.50	1.39 [1.08-2.32]	2.82 \pm 1.84	2.0 (0-11)
Male ($n=308$)	2.55 \pm 1.92	2.14 [1.24-3.16]	1.81 \pm 1.62	1.32 [0.53-2.31]	3.23 \pm 1.80	3.0 (0-9)
Age (years)						
< 35 ($n=40$)	1.77 \pm 1.18	1.51 [0.85-2.54]	1.46 \pm 1.06	1.17 [0.52-2.20]	2.80 \pm 1.80	2.0 (1-8)
36-65 ($n=223$)	2.62 \pm 2.20	1.97 [1.25-3.27]	1.98 \pm 1.75	1.42 [1.07-2.38]	3.17 \pm 1.90	3.0 (0-11)
> 66 ($n=375$)	2.21 \pm 1.54	1.78 [1.14-2.78]	1.80 \pm 1.48	1.34 [0.59-2.28]	2.95 \pm 1.79	3.0 (0-11)
Indication						
Bile duct stones ($n=261$)	1.97 \pm 1.40	1.54 [1.09-2.41]	1.67 \pm 1.38	1.29 [0.59-2.13]	2.21 \pm 1.35	2.0 (0-9)
Malignant strictures ($n=100$)	2.24 \pm 1.48	1.82 [1.18-3.01]	1.79 \pm 1.55	1.39 [0.56-2.35]	3.33 \pm 1.57	3.0 (0-8)
Jaundice ($n=80$)	2.71 \pm 2.02	2.22 [1.30-3.14]	1.99 \pm 1.57	1.54 [1.06-2.44]	3.34 \pm 1.95	3.0 (1-11)
Cholangitis ($n=61$)	2.60 \pm 2.21	2.12 [1.36-2.87]	1.80 \pm 1.25	1.43 [1.07-2.27]	3.30 \pm 1.68	3.0 (1-8)
Chronic pancreatitis ($n=28$)	2.61 \pm 2.37	2.00 [1.28-3.37]	2.19 \pm 1.74	1.94 [0.67-3.21]	3.46 \pm 2.19	3.0 (0-11)
Suspicion of bile duct injury ($n=22$)	3.90 \pm 2.65	3.61 [1.98-5.23]	2.25 \pm 1.87	1.77 [1.34-2.37]	4.68 \pm 1.56	5.0 (2-8)
Pseudocyst ($n=8$)	2.45 \pm 1.85	1.75 [1.06-3.77]	2.26 \pm 1.53	2.21 [0.68-3.95]	3.88 \pm 2.23	3.5 (2-9)
Stent exchange or removal ($n=36$)	2.19 \pm 1.65	1.38 [0.82-3.38]	2.15 \pm 2.25	1.31 [0.49-3.39]	3.44 \pm 2.05	3.0 (0-8)

Other (<i>n</i> =42)	2.68 ± 2.09	2.22 [1.30-3.49]	2.01 ± 1.97	1.19 [0.56-3.27]	3.83 ± 2.48	3.5 (1-11)
Type of ERCP						
Primary ERCP (<i>n</i> =463)	2.21 ± 1.67	1.80 [1.14-2.70]	1.74 ± 1.47	1.33 [0.58-2.19]	2.93 ± 1.81	2.0 (0-11)
Repeat ERCP (<i>n</i> =175)	2.63 ± 2.06	2.12 [1.19-3.53]	2.09 ± 1.75	1.45 [1.07-2.55]	3.25 ± 1.86	3.0 (0-11)
Primary endoscopist						
1 (<i>n</i> =168)	2.42 ± 2.09	1.69 [1.09-3.24]	2.11 ± 1.87	1.39 [1.01-3.06]	3.17 ± 2.10	3.0 (0-11)
2 (<i>n</i> =59)	1.88 ± 1.19	1.67 [0.92-2.39]	0.92 ± 0.91	0.52 [0.37-1.29]	3.27 ± 1.78	3.0 (1-11)
3 (<i>n</i> =229)	2.41 ± 1.81	2.04 [1.30-2.98]	1.81 ± 1.40	1.45 [1.07-2.29]	3.14 ± 1.76	3.0 (0-9)
4 (<i>n</i> =132)	2.24 ± 1.73	1.73 [1.07-2.50]	1.79 ± 1.58	1.31 [1.07-2.16]	2.63 ± 1.57	2.0 (0-9)
5 (<i>n</i> =50)	2.39 ± 1.31	2.24 [1.45-3.05]	2.25 ± 1.27	2.17 [1.40-3.16]	2.64 ± 1.74	2.0 (0-8)
Post-ERCP diagnosis						
Normal anatomy (<i>n</i> =65)	1.63 ± 1.06	1.34 [0.83-2.12]	1.18 ± 0.87	1.15 [0.48-1.43]	2.49 ± 1.64	2.0 (1-7)
Bile duct stricture (<i>n</i> =174)	2.37 ± 1.71	1.86 [1.23-2.80]	1.89 ± 1.59	1.43 [1.01-2.43]	3.64 ± 1.83	3.0 (0-11)
Bile duct stones (<i>n</i> =208)	2.10 ± 1.47	1.71 [1.14-2.56]	1.82 ± 1.43	1.34 [1.07-2.18]	2.22 ± 1.35	2.0 (0-9)
Cholangitis (<i>n</i> =48)	2.66 ± 2.40	1.88 [1.50-2.88]	1.82 ± 1.25	1.43 [1.09-2.44]	3.19 ± 1.62	3.0 (1-8)
Chronic pancreatitis (<i>n</i> =26)	2.62 ± 2.48	2.00 [1.07-3.37]	2.48 ± 2.27	1.97 [0.95-3.47]	3.23 ± 1.77	3.0 (0-7)
Pseudocyst (<i>n</i> =6)	2.19 ± 2.04	1.38 [0.90-3.36]	1.46 ± 1.50	0.82 [0.43-2.59]	3.33 ± 1.03	4.0 (2-4)
Bile duct dilatation (<i>n</i> =20)	2.13 ± 1.41	1.62 [1.10-2.80]	1.61 ± 1.52	1.09 [0.47-2.93]	3.60 ± 2.14	3.0 (1-9)
Bile duct injury (<i>n</i> =22)	4.04 ± 2.54	3.61 [2.38-5.23]	2.34 ± 1.84	1.77 [1.36-2.69]	4.77 ± 1.45	5.0 (2-8)
Stent problems (<i>n</i> =16)	2.28 ± 1.68	1.82 [0.96-3.37]	1.95 ± 1.82	1.11 [0.43-4.05]	2.69 ± 1.82	2.0 (0-7)
Pancreatic duct leakage (<i>n</i> =12)	3.66 ± 1.53	3.54 [2.38-4.44]	3.20 ± 1.95	3.23 [1.70-4.22]	4.25 ± 2.77	4.0 (1-11)

Other (<i>n</i> =41)	2.66 ± 2.20	2.15 [1.08-3.49]	1.88 ± 1.92	1.14 [0.51-2.35]	3.39 ± 2.32	3.0 (0-9)
Complexity level of ERCP						
1 (<i>n</i> =125)	2.22 ± 1.76	1.73 [0.98-2.78]	1.77 ± 1.71	1.31 [0.50-2.34]	3.46 ± 1.90	3.0 (0-9)
2 (<i>n</i> =381)	2.18 ± 1.76	1.74 [1.11-2.68]	1.65 ± 1.40	1.27 [0.58-2.17]	2.91 ± 1.80	2.0 (0-11)
3 (<i>n</i> =132)	2.84 ± 1.85	2.32 [1.40-3.67]	2.45 ± 1.71	2.02 [1.27-3.37]	2.89 ± 1.80	2.0 (0-11)
Cannulation difficulty of ERCP						
1 (<i>n</i> =216)	2.18 ± 1.71	1.67 [1.08-2.79]	1.61 ± 1.47	1.25 [0.52-2.15]	2.89 ± 1.80	2.0 (0-11)
2 (<i>n</i> =181)	2.20 ± 1.82	1.74 [1.13-2.65]	1.63 ± 1.40	1.25 [0.54-2.12]	2.98 ± 1.66	3.0 (0-8)
3 (<i>n</i> =140)	2.61 ± 1.63	2.24 [1.49-3.23]	2.28 ± 1.54	1.59 [1.23-3.16]	3.08 ± 1.80	3.0 (0-9)

ERCP indicates endoscopic retrograde cholangiopancreatography, *SD* standard deviation, *IQR* interquartile range

Table 3 The distribution of ERCP procedural complexity by endoscopist

Endoscopist	Total	Complexity level of ERCP		
		Grade 1	Grade 2	Grade 3
1	168	34 (20.2%)	90 (53.6%)	44 (26.2%)
2	59	9 (15.3%)	39 (66.1%)	11 (18.6%)
3	229	52 (22.7%)	139 (60.7%)	38 (16.6%)
4	132	18 (13.6%)	76 (57.6%)	38 (28.8%)
5	50	12 (24.0%)	37 (74.0%)	1 (2.0%)
Total	638	125 (19.6%)	381 (59.7%)	132 (20.7%)

ERCP indicates endoscopic retrograde cholangiopancreatography

Table 4 Univariate and multivariate analysis of factors influencing on dose area product (DAP) in 638 ERCP procedures

Variables	Univariate analysis		Multivariate analysis					
	log DAP ($Gy \cdot m^2$) ^a		Model 1		Model 2		Model 3	
	mean (SE)	<i>p</i> -value ^b	mean (SE)	<i>p</i> -value ^b	mean (SE)	<i>p</i> -value ^b	mean (SE)	<i>p</i> -value ^b
Gender								
Female	0.53 (0.04)	<i>0.003</i>	0.64 (0.06)	<i>0.023</i>	0.79 (0.32)	<i>0.048</i>	0.83 (0.31)	<i>0.025</i>
Male	0.69 (0.04)		0.76 (0.06)		0.89 (0.32)		0.95 (0.31)	
Age (years)								
< 35	0.33 (0.11)	Ref	0.51 (0.11)	Ref	0.67 (0.33)	Ref	0.73 (0.33)	Ref
36-65	0.70 (0.05)	<i>0.004</i>	0.83 (0.06)	<i>0.008</i>	0.96 (0.32)	<i>0.022</i>	1.01 (0.31)	<i>0.026</i>
> 66	0.58 (0.04)		0.76 (0.06)	<i>0.048</i>	0.89 (0.32)		0.93 (0.31)	
Indication								
Bile duct stones	0.48 (0.04)	Ref		NI		NI		NI
Malignant strictures	0.59 (0.07)							
Jaundice	0.78 (0.08)	<i>0.008</i>						
Cholangitis	0.71 (0.09)							
Chronic pancreatitis	0.66 (0.13)							
Suspicion of bile duct injury	1.13 (0.15)	<i><0.001</i>						
Pseudocyst	0.67 (0.24)							

1								
2								
3								
4								
5	Stent exchange or removal	0.49 (0.11)						
6	Other	0.72 (0.11)						
7								
8	Type of ERCP							
9								
10	Primary ERCP	0.58 (0.03)	NS		NI		NI	NI
11	Repeat ERCP	0.69 (0.06)						
12								
13	Primary endoscopist							
14								
15	1	0.58 (0.05)	NS		NI		NI	NI
16	2	0.46 (0.09)	Ref					
17								
18	3	0.67 (0.05)						
19	4	0.56 (0.06)						
20	5	0.71 (0.10)						
21								
22								
23	Radiographer							
24	1	0.20 (0.07)	Ref	0.26 (0.08)	Ref	0.41 (0.32)	Ref	0.47 (0.32)
25	2	0.73 (0.06)	<0.001	0.86 (0.08)	<0.001	1.01 (0.32)	<0.001	1.06 (0.31)
26								<0.001
27	3	0.60 (0.18)		0.75 (0.21)		0.86 (0.38)		0.91 (0.38)
28								
29	4	0.69 (0.08)	<0.001	0.74 (0.10)	<0.001	0.89 (0.33)	<0.001	0.93 (0.32)
30								<0.001
31	5	0.71 (0.08)	<0.001	0.79 (0.08)	<0.001	0.92 (0.32)	<0.001	0.97 (0.31)
32								<0.001
33	6	1.26 (0.10)	<0.001	1.30 (0.10)	<0.001	1.46 (0.33)	<0.001	1.52 (0.32)
34								<0.001
35	7	0.21 (0.13)		0.33 (0.12)		0.48 (0.34)		0.51 (0.34)
36								
37	8	0.44 (0.06)		0.47 (0.08)		0.60 (0.32)		0.64 (0.31)
38								
39	9	0.79 (0.14)	<0.001	0.82 (0.13)	<0.001	0.94 (0.34)	<0.001	1.00 (0.33)
40								<0.001
41								
42								
43								
44								
45								
46								
47								

10	0.68 (0.07)	<0.001	0.71 (0.90)	<0.001	0.85 (0.33)	<0.001	0.90 (0.32)	<0.001	
Complexity level of ERCP									
1	0.52 (0.06)	<0.001	0.57 (0.08)	<0.001	0.78 (0.35)		0.83 (0.34)		
2	0.55 (0.04)	<0.001	0.60 (0.06)	<0.001	0.74 (0.32)	0.014	0.79 (0.32)	0.018	
3	0.86 (0.06)	Ref	0.93 (0.08)	Ref	1.00 (0.30)	Ref	1.05 (0.29)	Ref	
Cannulation difficulty of ERCP									
1	0.54 (0.05)	0.002	0.57 (0.06)	<0.001	0.70 (0.32)	<0.001	0.76 (0.31)	<0.001	
2	0.56 (0.05)	0.006	0.65 (0.07)	<0.001	0.79 (0.32)	<0.001	0.84 (0.31)	<0.001	
3	0.78 (0.06)	Ref	0.88 (0.07)	Ref	1.03 (0.32)	Ref	1.08 (0.32)	Ref	
Post-ERCP diagnosis									
Normal anatomy	0.29 (0.08)	Ref	0.36 (0.09)	Ref	0.61 (0.34)	Ref		NI	
Bile duct stricture	0.66 (0.05)	<0.001	0.72 (0.07)	<0.001	0.78 (0.33)				
Bile duct stones	0.54 (0.05)		0.53 (0.06)		0.77 (0.33)				
Cholangitis	0.72 (0.10)	0.01	0.76 (0.09)	0.01	0.88 (0.33)				
Chronic pancreatitis	0.64 (0.13)		0.60 (0.12)		0.76 (0.32)				
Pseudocyst	0.51 (0.28)		0.70 (0.26)		0.78 (0.43)				
Bile duct dilatation	0.57 (0.15)		0.54 (0.15)		0.80 (0.37)				
Bile duct injury	1.20 (0.15)	<0.001	1.24 (0.13)	<0.001	1.32 (0.35)	<0.001			
Stent problems	0.52 (0.17)		0.64 (0.18)		0.70 (0.37)				
Pancreatic duct leakage	1.22 (0.20)	<0.001	0.89 (0.20)		0.96 (0.36)				
Other	0.65 (0.11)		0.72 (0.10)	0.03	0.90 (0.33)				

Types of interventions

Sphincterotomy	NI	NI	0.79 (0.32)		0.84 (0.32)	
Biliary stone extraction			0.86 (0.34)		0.91 (0.33)	
Bile duct dilatation			0.88 (0.33)		0.95 (0.33)	
Biliary stent placement			0.95 (0.34)	0.027	1.03 (0.33)	0.004
Biliary stent removal			0.79 (0.33)		0.85 (0.32)	
Pancreatic sphincterotomy			0.88 (0.34)		0.91 (0.33)	
Pancreatic stone extraction			0.79 (0.48)		0.86 (0.48)	
Pancreatic duct dilatation			0.79 (0.38)		0.84 (0.36)	
Pancreatic stent placement			0.96 (0.36)		1.06 (0.35)	
Pancreatic stent removal			0.89 (0.39)		0.95 (0.37)	
Brushing			0.88 (0.34)		0.96 (0.33)	

ERCP indicates endoscopic retrograde cholangiopancreatography, ^a distribution of DAP is presented on a logarithmic scale, ^b Bonferroni adjusted p-values, *SE* standard error, *Ref* reference category, *NS* not significant, *NI* not included

Types of interventions performed during ERCP were included directly in multivariate analysis

Table 5 Univariate and multivariate analysis of factors influencing on fluoroscopy time (FT) in 638 ERCP procedures

Variables	Univariate analysis		Multivariate analysis					
	log FT (min) ^a		Model 1		Model 2		Model 3	
	mean (SE)	<i>p</i> -value ^b	mean (SE)	<i>p</i> -value ^b	mean (SE)	<i>p</i> -value ^b	mean (SE)	<i>p</i> -value ^b
Gender								
Female	0.34 (0.04)	NS		NI		NI		NI
Male	0.23 (0.05)							
Age (years)								
< 35	0.06 (0.13)	Ref		NI		NI		NI
36-65	0.34 (0.06)	NS						
> 66	0.27 (0.04)							
Indication								
Bile duct stones	0.21 (0.05)	Ref		NI		NI		NI
Malignant strictures	0.25 (0.08)	NS						
Jaundice	0.40 (0.09)							
Cholangitis	0.32 (0.11)							
Chronic pancreatitis	0.41 (0.16)							
Suspicion of bile duct injury	0.58 (0.18)							
Pseudocyst	0.53 (0.30)							

1									
2									
3									
4									
5	Stent exchange or removal	0.23 (0.14)							
6	Other	0.29 (0.13)							
7									
8	Type of ERCP								
9	Primary ERCP	0.25 (0.04)	NS		NI		NI		NI
10	Repeat ERCP	0.39 (0.07)							
11									
12	Primary endoscopist								
13									
14	1	0.38 (0.06)	<0.001	0.58 (0.10)	<0.001	1.22 (0.41)	<0.001	1.50 (0.40)	<0.001
15	2	-0.42 (0.11)	Ref	-0.26 (0.11)	Ref	0.31 (0.41)	Ref	0.61 (0.39)	Ref
16	3	0.32 (0.05)	<0.001	0.45 (0.07)	<0.001	1.08 (0.41)	<0.001	1.39 (0.39)	<0.001
17	4	0.28 (0.07)	<0.001	0.37 (0.08)	<0.001	0.95 (0.41)	<0.001	1.22 (0.39)	<0.001
18	5	0.63 (0.11)	<0.001	0.83 (0.12)	<0.001	1.45 (0.42)	<0.001	1.72 (0.40)	<0.001
19									
20									
21									
22	Radiographer								
23									
24	1	0.14 (0.09)	Ref		NI		NI		NI
25	2	0.30 (0.08)	NS						
26	3	0.34 (0.23)							
27	4	0.35 (0.11)							
28	5	0.35 (0.10)							
29	6	0.53 (0.13)							
30	7	0.28 (0.17)							
31	8	0.14 (0.08)							
32	9	0.49 (0.18)							
33	10	0.30 (0.09)							
34									
35									
36									
37									
38									
39									
40									
41									
42									
43									
44									
45									
46									
47									

Complexity level of ERCP

1	0.13 (0.07)	<0.001	0.19 (0.09)	<0.001	0.86 (0.44)		1.15 (0.43)	
2	0.21 (0.04)	<0.001	0.28 (0.07)	<0.001	0.92 (0.41)	0.024	1.20 (0.39)	0.026
3	0.65 (0.07)	Ref	0.71 (0.09)	Ref	1.23 (0.39)	Ref	1.51 (0.37)	Ref

Cannulation difficulty of ERCP

1	0.13 (0.06)	<0.001	0.20 (0.07)	<0.001	0.79 (0.41)	<0.001	1.08 (0.39)	<0.001
2	0.18 (0.06)	<0.001	0.29 (0.07)	<0.001	0.92 (0.41)	<0.001	1.20 (0.39)	<0.001
3	0.61 (0.07)	Ref	0.69 (0.08)	Ref	1.31 (0.41)	Ref	1.58 (0.39)	Ref

Post-ERCP diagnosis

Normal anatomy	-0.12 (0.10)	Ref	0.05 (0.11)	Ref	0.71 (0.43)	Ref		NI
Bile duct stricture	0.32 (0.06)	<0.001	0.41 (0.07)	0.03	0.95 (0.42)			
Bile duct stones	0.32 (0.06)	<0.001	0.28 (0.07)		0.87 (0.42)			
Cholangitis	0.33 (0.12)		0.51 (0.12)	0.04	0.90 (0.42)			
Chronic pancreatitis	0.48 (0.16)	0.02	0.49 (0.15)		1.19 (0.41)			
Pseudocyst	-0.02 (0.34)		0.13 (0.33)		0.86 (0.54)			
Bile duct dilatation	0.08 (0.19)		0.08 (0.19)		0.77 (0.46)			
Bile duct injury	0.66 (0.18)	<0.001	0.78 (0.17)	<0.001	1.23 (0.44)			
Stent problems	0.13 (0.21)		0.43 (0.23)		0.90 (0.47)			
Pancreatic duct leakage	0.93 (0.24)	< 0.001	0.90 (0.25)	0.02	1.76 (0.46)	0.03		
Other	0.21 (0.13)		0.26 (0.13)		0.89 (0.42)			

Types of interventions

Sphincterotomy		NI		NI	1.01 (0.41)		1.28 (0.40)	
----------------	--	----	--	----	-------------	--	-------------	--

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

Biliary stone extraction	1.08 (0.43)		1.33 (0.41)	
Bile duct dilatation	1.13 (0.42)	0.037	1.43 (0.41)	0.014
Biliary stent placement	1.13 (0.43)		1.44 (0.41)	0.008
Biliary stent removal	1.08 (0.42)		1.36 (0.40)	
Pancreatic sphincterotomy	1.11 (0.43)		1.39 (0.41)	
Pancreatic stone extraction	1.12 (0.61)		1.33 (0.60)	
Pancreatic duct dilatation	0.94 (0.48)		1.40 (0.45)	
Pancreatic stent placement	1.01 (0.45)		1.40 (0.43)	
Pancreatic stent removal	1.07 (0.49)		1.54 (0.46)	
Brushing	1.29 (0.44)	0.002	1.56 (0.41)	0.001

ERCP indicates endoscopic retrograde cholangiopancreatography, ^a distribution of FT is presented on a logarithmic scale, ^b Bonferroni adjusted p-values, *SE* standard error, *Ref* reference category, *NS* not significant, *NI* not included

Types of interventions performed during ERCP were included directly in multivariate analysis

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Fig. 1 The distribution of dose area product (DAP) by radiographer controlled fluoroscopy system during endoscopic retrograde cholangiopancreatography (ERCP)

21x16mm (300 x 300 DPI)

Peer Review Only